Benjamin H. Lowentritt, MD, FACS, Discusses Future Analyses for the Phase 3 SPOTLIGHT Trial in Recurrent Prostate Cancer

Video

Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.

In an interview with CancerNetwork® during the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin H. Lowentritt, MD, FACS, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, highlighted next steps for the phase 3 SPOTLIGHT study (NCT04186845), which examined the impact of clinical factors on detection rates of 18F-rhPSMA-7.3 in suspected recurrent prostate cancer. In terms of future analyses, Lowentritt indicated that assessing sites of disease recurrence and levels of intensity will be areas of focus.

Transcript:

The SPOTLIGHT trial data are really just coming to light and being reported. We're continuing to look at different subgroup analyses. [We are] also really drilling into some of the sites of recurrence and identifying where and when this may be most helpful. [We are] evaluating different levels of intensity, the [standardized uptake value], and other things within the actual imaging reports and how that may predict sites of disease. There is certainly continuing to be a lot of work done with the data from the SPOTLIGHT trial, which was only recently completed.

Reference

Lowentritt, B. Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Related Content